Patrick Wood
Stock Analyst at Morgan Stanley
(2.23)
# 2,736
Out of 5,163 analysts
121
Total ratings
43.75%
Success rate
-1.79%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $21.59 | +15.79% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $41.46 | +25.42% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $70.77 | +20.11% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $69.13 | +70.69% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $69.92 | +18.71% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $123.48 | +9.33% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $7.33 | +36.43% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $27.13 | +87.98% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $64.24 | +16.75% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $159.36 | +31.78% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $17.40 | -13.79% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $16.20 | +29.63% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $77.32 | +3.47% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $214.57 | +37.48% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $81.81 | -0.99% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $66.76 | +54.28% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $97.02 | -25.79% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $107.32 | +61.20% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $219.84 | +44.20% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $18.84 | +96.39% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.72 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $21.59
Upside: +15.79%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $41.46
Upside: +25.42%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $70.77
Upside: +20.11%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $69.13
Upside: +70.69%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $69.92
Upside: +18.71%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $123.48
Upside: +9.33%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.33
Upside: +36.43%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $27.13
Upside: +87.98%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $64.24
Upside: +16.75%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $159.36
Upside: +31.78%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $17.40
Upside: -13.79%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.20
Upside: +29.63%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $77.32
Upside: +3.47%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $214.57
Upside: +37.48%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $81.81
Upside: -0.99%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $66.76
Upside: +54.28%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $97.02
Upside: -25.79%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $107.32
Upside: +61.20%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $219.84
Upside: +44.20%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $18.84
Upside: +96.39%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.72
Upside: -